← Back to Search

US-guided Proximal GON Block (Group P) for Migraine (GON Trial)

N/A
Waitlist Available
Led By Anuj Bhatia, MD FRCPC
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours and 3 months
Awards & highlights

Summary

Headache is one of the most common reasons for patients to access healthcare. Greater occipital nerve (GON) block with local anesthetic and steroid has been described for the management of primary headache refractory to conventional treatment. Two ultrasound (US)-guided techniques for greater occipital nerve (GON) block have been described for the management of refractory headache syndromes: a proximal technique performed at the level of the second cervical vertebra and a distal technique performed at the level of the superior nuchal line. Our airm is to compare the accuracy, efficacy and safety of these two techniques in patients with refractory headaches.

Eligible Conditions
  • Migraine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours and 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Efficacy-Related Outcomes
Performance-Related Outcomes
Safety-Related Outcomes

Trial Design

2Treatment groups
Active Control
Group I: US-guided Proximal GON Block (Group P)Active Control1 Intervention
Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.
Group II: US-guided Distal GON Block (Group D)Active Control1 Intervention
Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,518 Previous Clinical Trials
503,085 Total Patients Enrolled
Anuj Bhatia, MD FRCPCPrincipal InvestigatorUniversity Health Network, Toronto
3 Previous Clinical Trials
385 Total Patients Enrolled
~4 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top